Assessment of the quality of life of patients with cancer: Current state of the problem

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The successes of modern medicine in the treatment of malignant neoplasms have led to increased interest in the study of quality of life (QOL), which is considered one of the endpoints of modern clinical research in oncology. This study aimed to identify the main features of the current state and patterns of further development in assessing the QOL of patients with cancer. This study was based on a bibliographic search in PubMed and Google Scholar. A literature search was conducted using pairs of keywords “quality of life–oncology,” “quality of life–cancer,” “quality of life–questionnaires–oncology,” “patient-reported outcome (PRO)–oncology,” and “quality-adjusted life-year (QALY)–oncology” for articles published from 2017 to 2022 in Russian and English. Further, the articles were identified manually through the article link lists. PROs are currently considered the generally accepted standard for collecting data on the subjective perception of patients with cancer regarding their health status. Numerous questionnaires for assessing QOL are available, but the Functional Assessment of Cancer Therapy–General and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire are preferred. The combination of advanced technologies allows the collection of more reliable PRO data. Thus, unified approaches for the application of PRO results in large clinical trials are necessary.

作者简介

Anna P. Alekseeva

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South-Ural State Medical University

编辑信件的主要联系方式.
Email: hramluk_ap@mail.ru
ORCID iD: 0000-0002-6621-0284

Clinical Pharmacologist, Postgraduate Student

俄罗斯联邦, Chelyabinsk; Chelyabinsk

参考

  1. Bernatskii AS, Vagaitseva MV, Demin EV, et al. Onco-psychology. The manual for. Oncologists and clinical psychologist. St. Petersburg. 2017. (In Russ).
  2. Spigel DR, McCleod M, Jotte RM, et al. Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153). Journal of Thoracic Oncology. 2019;14(9):1628–1639. doi: 10.1016/j.jtho.2019.05.010
  3. Haraldstad K, Wahl A, Andenaes R, et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019;28(10):2641–2650. doi: 10.1007/s11136-019-02214-9.
  4. Coens C, Pe M, Dueck AC, et al. international standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol. 2020;21(2):e83-e96. doi: 10.1016/S1470-2045(19)30790-9
  5. Bottomley A, Reijneveld JC, Koller M, et al Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019;121:55–63. doi: 10.1016/j.ejca.2019.08.016
  6. Kim J, Singh H, Ayalew K, et al. Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections. Clin Cancer Res. 2018;24(8):1780–1784. doi: 10.1158/1078-0432.CCR-17-2555
  7. Basch E. High compliance rates with patient-reported outcomes in oncology trials submitted to the US Food and Drug Administration. JNCI: J Natl Cancer Inst. 2019;111(5):437–439. doi: 10.1093/jnci/djy183
  8. Lobanov YuF, Skudarnov EV, Strozenko LA, et al. Kachestvo zhizni kak problema v zdravookhranenii: sovremennye tendentsii. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy. 2018;(5–1):235–239. (In Russ).
  9. Ionova TI, Nikitina TP, Novik AA, Snegovoy AV. Prakticheskie rekomendatsii po otsenke kachestva zhizni u onkologicheskikh bol’nykh. Zlokachestvennye opukholi. 2017;7(3):586–591. (In Russ).doi: 10.18027/2224-5057-20l7-7-3s2-586-59l
  10. Strelkova SD, Murzina GZ, Popova NM, Starovoytov SO. Otsenka kachestva zhizni patsientov so zlokachestvennymi novoobrazovaniyami. Modern Science. 2020;(10–11):272–277. (In Russ).
  11. l’rikh EA, Tambieva ZA, Urmancheeva AF, Kutusheva GF. Kachestvo zhizni onkoginekologicheskikh bol’nykh: kolichestvennye metodiki opredeleniya. Akusherstvo i Ginekologiya Sankt-Peterburga. 2020;(1–2):30–34. (In Russ).
  12. Luckett T, King MT, Butow PN, et al Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22(10):2179–2190. doi: 10.1093/annonc/mdq721
  13. Snyder CF, Dy SM, Hendricks DE, et al Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. Support Care Cancer. 2007;15:1075–1085. doi: 10.1007/s00520-007-0223-1
  14. Keller SD, Bayliss MS, Ware JE, et al. Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods. Health Serv Res. 1997;32(3):367. https://pubmed.ncbi.nlm.nih.gov/9240286/
  15. Campolina AG, Lopez RVM, Nardi EP, Ferraz MB. Quality of life in a sample of Brazilian adults using the generic SF-12 questionnaire. Rev Assoc Méd Bras. 2018;64(3):234–242. doi: 10.1590/1806-9282.64.03.234
  16. Van Leeuwen M, Husson O, Alberti P, et al. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes. 2018;16(1):1–15. doi: 10.1186/s12955-018-0920-0
  17. Bottomley A, Reijneveld JC, Koller M, et al. Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019;(121):55–63. doi: 10.1016/j.ejca.2019.08.016
  18. Raymakers AJN, Regier DA, Peacock SJ. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. Cancer. 2020;126(1):148–155. doi: 10.1002/cncr.32455
  19. Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715. doi: 10.1016/j.jval.2012.02.008
  20. Pequeno NPF, Cabral NLA, Marchiona DM, et al. Quality of life assessment instruments for adults: a systematic review of population-based studies. Health Qual Life Outcomes. 2020;18(1):1–13. doi: 10.1186/s12955-020-01347-7
  21. Hauth F, Bizu V, App R, et al. electronic patient-reported outcome measures in radiation oncology: Initial experience after workflow implementation. JMIR Mhealth Uhealth. 2019;7(7):e12345. doi: 10.2196/12345
  22. Lundy JJ, Coon CD, Fu AC, Pawar V. Collection of post-treatment PRO data in oncology clinical trials. Ther Innov Regul Sci. 2021;55(1):111–117. doi: 10.1007/s43441-020-00195-3
  23. Wintner LM, Sztankay M, Riedl D, et al. How to implement routine electronic patient-reported outcome monitoring in oncology rehabilitation. Int J Clin Pract. 2021;75(4):e13694. doi: 10.1111/ijcp.13694
  24. Warsame R, D’Souza A. Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology. Mayo Clin Proc. 2019;94(11):2291–2301. doi: 10.1016/j.mayocp.2019.04.005

版权所有 © Alekseeva A., 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##